Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K+ Channel

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  El Harchi, Aziza ^a   Melgari, Dario ^a   Zhang, Yi Hong ^a   Zhang, Henggui ^b   Hancox, Jules C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISOPYRAMIDE; FLECAINIDE; POTASSIUM CHANNEL HERG; QUINIDINE; SOTALOL;

ACTION POTENTIAL; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR RECORDING; PATCH CLAMP; PHARMACOGENETICS; POTASSIUM CURRENT; PROTEIN EXPRESSION; SHORT QT SYNDROME; VOLTAGE CLAMP; WHOLE CELL; WILD TYPE;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ELECTRIC CONDUCTIVITY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART CONDUCTION SYSTEM; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HEK293 CELLS; HUMANS; MUTAGENESIS; MUTATION; PATCH-CLAMP TECHNIQUES; QUINIDINE; TEMPERATURE; TIME FACTORS;

EID: 84871532144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052451     Document Type: Article

References (52)

1. Sanguinetti MC, Jurkiewicz NK, (1990) Two components of cardiac delayed rectifier K+ current. J Gen Physiol 96: 195-215.
2. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E, (2004) Pharmacology of cardiac potassium channels. Cardiovasc Res 62: 9-33.
3. Sanguinetti MC, Jiang C, Curran ME, Keating MT, (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
4. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA, (1995) HERG, an inward rectifier in the voltage-gated potassium channel family. Science 269: 92-95.
5. Weirich J, Antoni H, (1998) Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Res Cardiol 93 S1: 125-132.
6. Witchel HJ, Hancox JC, (2000) Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium channel. Clinical and Experimental Pharmacology and Physiology 27: 753-766.
7. Sanguinetti MC, Mitcheson JS, (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. TIPS 26: 119-124.
8. Hancox JC, McPate MJ, El Harchi A, Zhang YH, (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacology and Therapeutics 119: 118-132.
9. Sanguinetti MC, Tristani-Firouzi M, (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
10. Modell SM, Lehmann MH, (2006) The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med 8: 143-155.
11. Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M, (2005) Short QT syndrome. Cardiovasc Res 67: 357-366.
12. Maury P, Extramiana F, Sbragia P, Giustetto C, Schimpf R, et al. (2008) Short QT syndrome. Update on a recent entity. Arch Cardiovasc Dis 101: 779-786.
13. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, et al. (2004) Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109: 30-35.
14. Hong K, Bjeerregaard P, Gussak I, Brugada R, (2005) Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovas Electophysiol 16: 394-396.
15. Cordeiro JM, Brugada R, Wu YS, Hong K, Dumaine R, (2005) Modulation of IKr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovas Res 67: 498-509.
16. McPate MJ, Duncan RS, Milnes JT, Witchel HJ, Hancox JC, (2005) The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37°C. Biochem Biophys Res Comm 334: 441-449.
17. Giustetto C, Di MF, Wolpert C, Borggrefe M, Schimpf R, et al. (2006) Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 27: 2440-2447.
18. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro JM, et al. (2005) Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovas Electophysiol 16: 54-58.
19. Schimpf R, Veltmann C, Giustetto C, Gaita F, Borgreffe M, (2007) In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. J Cardiovas Electophysiol 18: 1157-1160.
20. McPate MJ, Duncan RS, Witchel HJ, Hancox JC, (2006) Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 41: 563-566.
21. McPate MJ, Duncan RS, Hancox JC, Witchel HJ, (2008) Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol 155: 957-966.
22. Hassel D, Scholz EP, Trano N, Friedrich O, Just S, et al. (2008) Deficient zebrafish ether-a-go-go-related gene channel gating causes short-QT syndrome in zebrafish reggae mutants. Circulation 117: 866-875.
23. Zhang YH, Colenso CK, Sessions RB, Dempsey CE, Hancox JC, (2011) The hERG K+ channel S4 domain L532P mutation: characterization at 37°C. Biochim Biophys Acta 1808: 2477-2487.
24. Sun Y, Quan XQ, Fromme S, Cox RH, Zhang P, et al. (2011) A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol 50: 433-441.
25. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, et al. (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys 74: 230-241.
26. El Harchi A, Zhang YH, Hussein L, Dempsey CE, Hancox JC, (2012) Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol 52: 185-195.
27. El Harchi A, McPate MJ, Zhang YH, Zhang H, Hancox JC, (2009) Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome. J Mol Cell Cardiol 137: 83-85.
28. Levi AJ, Hancox JC, Howarth FC, Croker J, Vinnicombe J, (1996) A method for making rapid changes of superfusate whilst maintaining temperature at 37°C. Pflugers Arch 432: 930-937.
29. Sanguinetti MC, Curran ME, Spector PS (1995). Block of delayed rectifier K+ channels as an antiarrhythmic mechanism. In: Vereecke J, van Bogaert PP, Verdonck F, editors. Potassium channels in normal and pathological conditions. Leuven University Press. p. 151-66.
30. Du CY, Adeniran I, Cheng H, Zhang YH, El Harchi, et al. (2010) Acidosis Impairs the Protective Role of hERG K+ Channels Against Premature Stimulation. J Cardiovasc Electrophysiol 21: 1160-1169.
31. Smith PL, Baukrowitz T, Yellen G, (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-836.
32. Hancox JC, Levi AJ, Witchel HJ, (1998) Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. Pflugers Archiv- European Journal of Physiology 436: 843-853.
33. McPate MJ, Zhang H, Adeniran I, Cordeiro JM, Witchel HJ, et al. (2009) Comparative effects of the short QT N588K mutation at 37°C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study. J Physiol Pharmacol 60: 23-41.
34. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC, (2010) Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37°C: Cisapride versus dofetilide. J Pharmacol Toxicol Methods 61: 178-191.
35. Paul AA, Witchel HJ, Hancox JC, (2002) Inhibition of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136: 717-729.
36. Paul AA, Witchel HJ, Hancox JC, (2001) Inhibition of HERG potassium channel current by the Class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Comm 280: 1243-1250.
37. Lees-Miller JP, Subbotina JO, Guo J, Yarov-Yarovoy V, Noskov SY, et al. (2009) Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function. Biophys 96: 3600-3610.
38. Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI, (2008) Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 74: 1443-1452.
39. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM, (1998) Molecular determinants of dofetilide block of HERG K channels. Circ Res 82: 386-395.
40. Weerapura M, Hebert TE, Nattel S, (2002) Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch 443: 520-531.
41. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, et al. (2000) Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 87: 1012-1018.
42. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ, (2000) Molecular determinant of high affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Molecular Pharmacology 57: 367-374.
43. Kirsch GE, Trepakova ES, Brimecombe JC, Sidah SS, Erickson HD, et al. (2004) Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern J Pharmacol Toxicol Methods. 50: 93-101.
44. Yao JA, Du X, Lu D, Baker RL, Daharsh E, et al. (2005) Estimation of potency of hERG inhibitors: impact of voltage protocol and temperature. J Pharmacol Toxical Methods 52: 146-153.
45. Lu Y, MahautSmith MP, Varghese A, Huang CLH, Kemp PR, et al. (2001) Effects of premature stimulation on HERG channels. J Physiol 537 (3):: 843-851.
46. Adeniran I, McPate MJ, Witchel HJ, Hancox JC, Zhang H, (2011) Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndrome. PLoS Comput Biol 7(12): e1002313.
47. Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, et al. (2003) Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 14: 1273-1277.
48. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, et al. (2011) Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 58: 587-595.
49. Viskin S, Antzelevitch C, Marquez MF, Belhassen B, (2007) Quinidine: a valuable medication joins the list of 'endangered species'. Europace 9(12): 1105-1106.
50. Zema MJ, (1984) Serum drug concentration and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation. Ther Drug Monit 6: 192-198.
51. Breindahl T, (2000) Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 746: 249-254.
52. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, et al. (2004) Short QT syndrome: Pharmacological treatment. J Am Coll Cardiol 43: 1494-1499.